Home » Newsletters » BioWorld Asia

BioWorld Asia

March 15, 2000

View Archived Issues

Transghne Seeks To Capitalize On Upsurge Via $96.5M Funding

Cannabis Compounds Show Benefit In Treating Gliomas

Xenova Moving Into Phase III With Proprietary Cancer Drug

Irish Officials Make Biotech A Priority Via $684M Fund

European Union Defers Voting On 3 GM Product Applications

Cyclacel Establishes Unit At Cambridge For Cancer Work

D-Pharm Takes Stroke Drug Into Clinic, Opens U.S. Office

Amrad Ready To Move Pain, HBV Products Into The Clinic

Proneuron Raises $3.7M For Work In Spinal Cord Therapy

Ceres, Genset Finish Project In Plant Functional Genomics

Phase I Results Bode Well For Cancer Immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...